Cargando…
Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Association of Urology. Published by Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864103/ https://www.ncbi.nlm.nih.gov/pubmed/35248411 http://dx.doi.org/10.1016/j.eururo.2022.02.016 |
| _version_ | 1784655380424425472 |
|---|---|
| author | Welén, Karin Rosendal, Ebba Freyhult, Eva Oh, William K. Gisslén, Magnus Ahlm, Clas Connolly, Anne-Marie Fors Överby, Anna K. Josefsson, Andreas |
| author_facet | Welén, Karin Rosendal, Ebba Freyhult, Eva Oh, William K. Gisslén, Magnus Ahlm, Clas Connolly, Anne-Marie Fors Överby, Anna K. Josefsson, Andreas |
| author_sort | Welén, Karin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8864103 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Association of Urology. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88641032022-02-23 Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients Welén, Karin Rosendal, Ebba Freyhult, Eva Oh, William K. Gisslén, Magnus Ahlm, Clas Connolly, Anne-Marie Fors Överby, Anna K. Josefsson, Andreas Eur Urol Letter to the Editor European Association of Urology. Published by Elsevier B.V. 2022-06 2022-02-23 /pmc/articles/PMC8864103/ /pubmed/35248411 http://dx.doi.org/10.1016/j.eururo.2022.02.016 Text en © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Welén, Karin Rosendal, Ebba Freyhult, Eva Oh, William K. Gisslén, Magnus Ahlm, Clas Connolly, Anne-Marie Fors Överby, Anna K. Josefsson, Andreas Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients |
| title | Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients |
| title_full | Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients |
| title_fullStr | Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients |
| title_full_unstemmed | Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients |
| title_short | Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients |
| title_sort | reply to carlos g. wambier and gerard j. nau’s letter to the editor re: karin welén, ebba rosendal, magnus gisslén, et al. a phase 2 trial of the effect of antiandrogen therapy on covid-19 outcome: no evidence of benefit, supported by epidemiology and in vitro data. eur urol. 2022;81:285–93. positive effects of enzalutamide for hospitalized covid-19 patients: still no positive effect of enzalutamide for hospitalized covid-19 patients |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864103/ https://www.ncbi.nlm.nih.gov/pubmed/35248411 http://dx.doi.org/10.1016/j.eururo.2022.02.016 |
| work_keys_str_mv | AT welenkarin replytocarlosgwambierandgerardjnauslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593positiveeffectsofenzalutamid AT rosendalebba replytocarlosgwambierandgerardjnauslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593positiveeffectsofenzalutamid AT freyhulteva replytocarlosgwambierandgerardjnauslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593positiveeffectsofenzalutamid AT ohwilliamk replytocarlosgwambierandgerardjnauslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593positiveeffectsofenzalutamid AT gisslenmagnus replytocarlosgwambierandgerardjnauslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593positiveeffectsofenzalutamid AT ahlmclas replytocarlosgwambierandgerardjnauslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593positiveeffectsofenzalutamid AT connollyannemariefors replytocarlosgwambierandgerardjnauslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593positiveeffectsofenzalutamid AT overbyannak replytocarlosgwambierandgerardjnauslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593positiveeffectsofenzalutamid AT josefssonandreas replytocarlosgwambierandgerardjnauslettertotheeditorrekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593positiveeffectsofenzalutamid |